LUGPA 2025 Global Prostate Cancer Congress Enduring Program-GPCC 2025 Session 9

Video Transcription

Video Summary

The meeting featured several expert talks focusing primarily on advances and challenges in managing metastatic castration-resistant prostate cancer (mCRPC), bone health, and patient perspectives. Dr. Dan Petrulak reviewed over 20 years of progress since docetaxel chemotherapy showed modest survival benefits, highlighting current multidrug regimens targeting hormones, chemotherapeutics, DNA repair, and theranostics like PSMA-targeted agents. He emphasized the importance of sequencing treatments, molecular profiling including microsatellite instability, and emerging immunotherapies such as bispecific T-cell engagers targeting STEEP1 and PSMA.<br /><br />Dr. Paul Miller discussed bone health management during androgen deprivation therapy (ADT), underscoring the accelerated bone loss and fracture risk it causes. He explained challenges in interpreting DEXA scans due to bone metastases and arthritis, advocated use of FRAX and Garvin scores for fracture risk assessment, and reviewed antiresorptive therapies like bisphosphonates and denosumab alongside vitamin D supplementation and exercise to maintain bone strength. He cautioned about overtreatment risks and insurance hurdles.<br /><br />Dr. Curtis Nickel shared personal insights after his diagnosis with high-volume metastatic prostate cancer, relating lessons on screening limits, treatment intensification (triplet therapy), managing side effects like chemotherapy toxicity, maintaining optimism, and addressing quality of life. He highlighted the emotional and practical challenges of navigating advanced disease and stressed empathy when discussing prognostic statistics.<br /><br />The session concluded with a case discussion illustrating the complexities of neuroendocrine differentiation in prostate cancer metastases, the need for biopsy and molecular testing to guide therapy choice, and the evolving landscape of systemic and immunotherapies. Overall, speakers emphasized the importance of individualized care incorporating new targeted treatments, supportive measures, and compassionate communication to improve outcomes and patient experience in advanced prostate cancer.

Keywords

metastatic castration-resistant prostate cancer

mCRPC

docetaxel chemotherapy

multidrug regimens

molecular profiling

immunotherapies

bone health management

androgen deprivation therapy

antiresorptive therapies

treatment intensification

neuroendocrine differentiation